Daratumumab can also exert a favourable immune modulatory activity in the TME of MM patients by depleting CD38+ MDSC via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytoxicity (CDC) (68). Here, CD38 is linked to Miyoshi myopathy.